Since HPV vaccines have not been proven to prevent cancer, the CDC lists three alternate ways to judge the vaccines’ efficacy. None of them work. Where does that leave medical consumers?
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Mar 19, 2011 – According to the prescribing information packet, GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:
• Cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11
• And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:
• Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS)
• Cervical intraepithelial neoplasia (CIN) grade 1
• Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
• Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of genital warts (condyloma acuminata) caused by HPV types 6 and 11.
The prescribing information packet for Gardasil’s competitor states: CERVARIX® is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies (14)]:
• Cervical cancer
• Cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and
• Cervical intraepithelial neoplasia (CIN) grade 1.
CERVARIX is approved for use in females 10 through 25 years of age.
Examine the facts. Neither vaccine has been proven to prevent cancer. The CDC says, “While there are well-established cancer registries in the United States, it will take decades before the impact of vaccine on cervical cancer is observed. More proximal measures of vaccine impact include outcomes such as prevalence of HPV vaccine types, incidence of cervical precancers and genital warts.”
HPV Prevalence: HPV tests currently available to American medical consumers generate both false positive and false negative reports. (See this report for verification.)
The only way left to monitor HPV vaccine efficacy is to determine whether the vaccine-related genotypes decline after vaccination. Without a reliable short target DNA sequencing test available to the general medical consumer, this is not possible.
This leaves people having to trust the authorities and wait for decades to see if HPV vaccines actually reduce the incidence of cervical cancer. The SaneVax Team believes this is not a viable option.
The CDC stressed the importance of post-vaccination HPV monitoring. Medical consumers need to know if they have been exposed to a vaccine-relevant HPV before vaccination not only to avoid potential serious side effects, but to avoid wasting their precious health care dollars on a vaccine that will do nothing for them if they have already been exposed.
Consider the following to results of searches of the VAERS database:
• 106 reports of anogenital warts found after HPV vaccination
• 222 reports of papillomavirus infections found after HPV vaccination
• 29 reports of cervical cancer after HPV vaccination
The VAERS database has its limitations, but for now it is the only adverse event reference source available to the public. The reports above may be related to HPV genotypes not included in the vaccines. Then again, they may be caused by the same genotypes included in the vaccines. Without proper DNA sequencing, no one will ever know.
When a vaccine has no proven efficacy against the disease it is intended to prevent, no risk to the consumer is acceptable.
3. http://www.ncbi.nlm.nih.gov/pubmed/12636951?dopt=Abstrac …